Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: An update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool

Canadian Journal of Gastroenterology

Volumn 19, Issue 5, 2005, Pages 285-303

  Veldhuyzen van Zanten, Sander J O ^a   Bradette, Marc ^b   Chiba, Naoki ^c,n   Armstrong, David ^c   Barkun, Alan ^d   Flook, Nigel ^e   Thomson, Alan ^e   Bursey, Ford ^f   Bartle, William ^g   Blackshaw, Patricia ^h   Craig, Brian ^a,i   Govender, Krishnasamy ^j   Marlow, Bernard ^k   McCammon, Richard ^l   Woodland, Robert ^m  

^a DALHOUSIE UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

^f MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h SURREY MEMORIAL HOSPITAL   (Canada)

ⁱ SAINT JOHN REGIONAL HOSPITAL   (Canada)

^j Surrey Memorial Hospital ^*  (Canada)

^k UNIVERSITY OF TORONTO   (Canada)

^l Grace Hospital Winnipeg   (Canada)

^m Health Care Corporation   (Canada)

ⁿ Surrey Gl Clinic   (Canada)

more..

Author keywords

Acetylsalicylic acid; Aspirin; Dyspepsia; Gastroesophageal reflux disease; NSAIDs; Systematic review

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTACID AGENT; ANTIDEPRESSANT AGENT; BISMUTH SALICYLATE; CELECOXIB; CIMETIDINE; CISAPRIDE; CLARITHROMYCIN; CYCLOOXYGENASE 2 INHIBITOR; DOMPERIDONE; ESOMEPRAZOLE; ETORICOXIB; FAMOTIDINE; GAVISCON; HISTAMINE H2 RECEPTOR ANTAGONIST; INDOMETACIN; LANSOPRAZOLE; MECLOFENAMIC ACID; METOCLOPRAMIDE; METRONIDAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PEPPERMINT OIL; PIROXICAM; PLACEBO; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; TETRACYCLINE; VALDECOXIB;

ANTIREFLUX OPERATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG MEGADOSE; DRUG SUBSTITUTION; DUODENUM ULCER; DYSPEPSIA; ENDOSCOPY; EVIDENCE BASED MEDICINE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LONG TERM CARE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SHORT COURSE THERAPY; STOMACH ULCER;

EID: 20444467682     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2005/674607     Document Type: Review

References (233)

1. Veldhuyzen van Zanten SJ, Flook N, Chiba N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ 2000;162(Suppl 12):S3-23.
2. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat ON. Functional gastroduodenal disorders. Gut 1999;45(Suppl 2):II37-42.
3. Chiba N, Van Zanten SJ, Sinclair P, Ferguson RA, Escobedo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: The Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002;324:1012-6.
4. Moayyedi P, Feltbower R, Brown J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: A randomised controlled trial. Leeds HELP Study Group. Lancet 2000;355:1665-9.
5. Wildner-Christensen M, Moller Hansen J, Schaffalitzky De Muckadell OB. Rates of dyspepsia one year after Helicobacter pylori screening and eradication in a Danish population. Gastroenterology 2003;125:372-9.
6. Thomson AB, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: The Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003;17:1481-91. (Erratum in 2004;20:72).
7. Talley NJ, Weaver AL, Tesmer DL, Zinsmeister AR. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology 1993;105:1378-86.
8. Barkun A, Bardou M, Marshall JK. Nonvariceal Upper GI Bleeding Consensus Conference Group. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003;139:843-57.
9. The Society for Surgery of the Alimentary Tract (SSAT), American Gastroenterological Association (AGA), American Society for Gastrointestinal Endoscopy (ASGE) Consensus Panel. Management of Barrett's esophagus. J Gastrointest Surg 2000;4:115-6.
10. Sampliner RE. The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002;97:1888-95.
11. Axon AT, Bell GD, Jones RH, Quine MA, McCloy RF. Guidelines on appropriate indications for upper gastrointestinal endoscopy. Working Party of the Joint Committee of the Royal College of Physicians of London, Royal College of Surgeons of England, Royal College of Anaesthetists, Association of Surgeons, the British Society of Gastroenterology, and the Thoracic Society of Great Britain. BMJ 1995;310:853-6.
12. de Wit NJ, Mendive J, Seifert B, Cardin F, Rubin G. Guidelines on the management of H pylori in primary care: Development of an implementation strategy. Fam Pract 2000;17(Suppl 2):S27-32.
13. Talley NJ, Axon A, Bytzer F, Holtmann G, Lam SK, van Zanten S. Management of uninvestigated and functional dyspepsia: A Working Party report for the World Congresses of Gastroenterology 1998. Aliment Pharmacol Ther 1999;13:1135-48.
14. The British Society of Gastroenterology guidelines on dyspepsia. London: British Society of Gastroenterology, 2002. www.bsg.org.uk/pdf_word_docs/dyspepsia.doc (Version current at February 15, 2005).
15. The Scottish Intercollegiate Guidelines Network (SIGN). Dyspepsia. Edinburgh: Scottish Intercollegiate Guidelines Network, 2003. http://www.sign.ac.uk/guidelines/fulltext/68/index.html (Version current at February 15, 2005).
16. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: A cost-utility analysis. Ann Intern Med 2003;138:176-86.
17. Canga C III, Vakil N. Upper GI malignancy, uncomplicated dyspepsia, and the age threshold for early endoscopy. Am J Gastroenterol 2002;97:600-3.
18. Breslin NP, Thomson AB, Bailey RJ, et al. Gastric cancer and other endoscopic diagnoses in patients with benign dyspepsia. Gut 2000;46:93-7.
19. Voutilainen M, Mantynen T, Kunnamo I, Juhola M, Mecklin JP, Farkkila M. Impact of clinical symptoms and referral volume on endoscopy for detecting peptic ulcer and gastric neoplasms. Scand J Gastroenterol 2003;38:109-13.
20. Meineche-Schmidt V, Jorgensen T. Alarm symptoms in patients with dyspepsia: A three-year prospective study from general practice. Scand J Gastroenterol 2002;37:999-1007.
21. Manes G, Balzano A, Marone P, Lioniello M, Mosca S. Appropriateness and diagnostic yield of upper gastrointestinal endoscopy in an open-access endoscopy system: A prospective observational study based on the Maastricht guidelines. Aliment Pharmacol Ther 2002;16:105-10.
22. Falk GW. Barrett's esophagus. Gastroenterology 2002;122:1569-91.
23. Avidan B, Sonnenberg A, Schnell TG, Sontag SJ. There are no reliable symptoms for erosive oesphagitis and Barrett's oesophagus: Endoscopic diagnosis is still essential. Aliment Pharmacol Ther 2002;16:735-42.
24. Avidan B, Sonnenberg A, Schnell TG, Sontag SJ. Hiatal hernia and acid reflux frequency predict presence and length of Barrett's esophagus. Dig Dis Sci 2002;47:256-64.
25. Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: A prospective controlled investigation. Am J Med 2001;111:33-7.
26. Katzka DA, Rustgi AK. Gastroesophageal reflux disease and Barrett's esophagus. Med Clin North Am 2000;84:1137-61.
27. National Cancer Institute of Canada. Canadian Cancer Statistics. Toronto: National Cancer Institute of Canada, 2002.
28. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
29. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett's esophagus and esophageal cancer: Scientific review. JAMA 2002;287:1972-81.
30. Avidan B, Sonnenberg A, Schnell TG, Chejfec G, Metz A, Sontag SJ. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002;97:1930-6.
31. Peterson WL, American Gastroenterological Association Consensus Development Panel. Improving the management of GERD: Evidence-based therapeutic strategies. Richmond: AGA Press 2002:1-21.
32. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607-19.
33. Spechler SJ. Clinical practice. Barrett's Esophagus. N Engl J Med 2002;346:836-42.
34. Fass R, Hell RW, Garewal HS, et al. Correlation of oesophageal acid exposure with Barrett's oesophagus length. Gut 2001;48:310-3.
35. Fass R, Ofman JJ. Gastroesophageal reflux disease - should we adopt a new conceptual framework? Am J Gastroenterol 2002;97:1901-9.
36. Csendes A, Burdiles P, Braghetto I, et al. Dysplasia and adenocarcinoma after classic antireflux surgery in patients with Barrett's esophagus: The need for long-term subjective and objective follow-up. Ann Surg 2002;235:178-85.
37. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: Follow-up of a randomized controlled trial. JAMA 2001;285:2331-8.
38. Fennerty MB, Triadafilopoulos G. Barrett's-related esophageal adenocarcinoma: Is chemoprevention a potential option? Am J Gastroenterol 2001;96:2302-5.
39. Armstrong D. Motion - all patients with GERD should be offered once in a lifetime endoscopy: Arguments for the motion. Can J Gastroenterol 2002;16:549-51.
40. Sonnenberg A, Soni A, Sampliner RE. Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma. Aliment Pharmacol Ther 2002;16:41-50.
41. Gudlaugsdottir S, van Blankenstein M, Dees J, Wilson JH. A majority of patients with Barrett's oesophagus are unlikely to benefit from endoscopic cancer surveillance. Eur J Gastroenterol Hepatol 2001;13:639-45.
42. Chiba N. Motion - screening and surveillance of Barrett's epithelium is practical and cost effective: Arguments against the motion. Can J Gastroenterol 2002;16:541-5.
43. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999;44(Suppl 2):S1-16.
44. Streitz JM Jr, Andrews CW Jr, Ellis FH Jr. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 1993;105:383-7.
45. van Sandick JW, van Lanschot JJ, Tytgat GN, Offerhaus GJ, Obertop H. Barrett oesophagus and adenocarcinoma: An overview of epidemiologic, conceptual and clinical issues. Scand J Gastroenterol 2001;234(Suppl):51-60.
46. Peters JH. The management of dysplastic Barrett's esophagus: Where do we go from here? Ann Surg Oncol 2002;9:215-6.
47. Macdonald CE, Wicks AC, Playford RJ. Final results from 10-year cohort of patients undergoing surveillance for Barrett's oesophagus: Observational study. BMJ 2000;321:1252-5.
48. Nietert PJ, Silverstein MD, Mokhashi MS, et al. Cost-effectiveness of screening a population with chronic gastroesophageal reflux. Gastrointest Endosc 2003;57:311-8.
49. Castell DO. Medical, surgical, and endoscopic treatment of gastroesophageal reflux disease and Barrett's esophagus. J Clin Gastroenterol 2001;33:262-6.
50. Peters FT, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999;45:489-94. (Erratum in 2000;47:154-5).
51. Corey KE, Schmitz BA, Shaheen NJ. Does surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barret's esophagus? A meta-analysis. Am J Gastroenterol 2003;98:2390-4.
52. Stichtenoth DO, Frolich JC. The second generation of COX-2 inhibitors: What advantages do the newest offer? Drugs 2003;63:33-45.
53. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
54. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
55. MacDonald TM, Morant SV, Robinson GC, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: Cohort study. BMJ 1997;315:1333-7.
56. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72. Erratum in: Lancet 1994;343:1048.
57. Ofman JJ, Maclean CH, Straus WL, et al. Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis Rheum 2003;49:508-18.
58. Laheij RJ, Jansen JB, Verbeek AL, Verheugt FW. Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease. Aliment Pharmacol Ther 2001;15:1055-9.
59. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: Meta-analysis. BMJ 2000;321:1183-7.
60. Straus WL, Ofman JJ, MacLean C, et al. Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions. Am J Gastroenterol 2002;97:1951-8.
61. Bannwarth B, Treves R, Euller-Ziegler L, Rolland D, Ravaud P, Dougados M. Adverse events associated with rofecoxib therapy: Results of a large study in community-derived osteoarthritic patients. Drug Saf 2003;26:49-54.
62. Goldstein JL, Kivitz AJ, Verburg KM, Recker DP, Palmer RC, Kent JD. A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. Aliment Pharmacol Ther 2003;18:125-32.
63. Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D. Gastroprotective therapy and risk of gastrointestinal ulcers: Risk reduction by COX-2 therapy. J Rheumatol 2002;29:467-73.
64. Makarowski W, Zhao WW, Bevirt T, Recker DP. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: A randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 2002;10:290-6.
65. Sikes DH, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 2002;14:1101-11.
66. Hunt RH, Harper S, Watson DJ, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003;98:1725-33.
67. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
68. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic-ulcer disease: A meta-analysis. Lancet 2002;359:14-22.
69. Lai KC, Lau CS, Ip, WY, et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: A double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2003;17:799-805.
70. Graham DY. NSAIDs, Helicobacter pylori, and Pandora's box. N Engl J Med 2002;347:2162-4.
71. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002;346:2033-8.
72. Holvoet J, Terriere L, Van Hee W, Verbist L, Fierens E, Hautekeete ML. Relation of upper gastrointestinal bleeding to nonsteroidal anti-inflammatory drugs and aspirin: A case-control study. Gut 1991;32:730-4.
73. Clinch D, Banerjee AK, Ostick G. Absence of abdominal pain in elderly patients with peptic ulcer. Age Ageing 1984;13:120-3.
74. Mellem H, Stave R, Myren J, et al. Symptoms in patients with peptic ulcer and hematemesis and/or melena related to the use of nonsteroid anti-inflammatory drugs. Scand J Gastroenterol 1985;20:1246-8.
75. Matthewson K, Pugh S, Northfield TC. Which peptic ulcer patients bleed? Gut 1988;29:70-4.
76. Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002;123:1006-12.
77. Chalmers TC, Berrier J, Hewitt P, et al. Meta-analysis of randomized controlled trials as a method of estimating rare complications of nonsteroidal anti-inflammatory drug therapy. Aliment Pharmacol Ther 1988;2(Suppl 1):9-26.
78. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-96.
79. van Pinxteren B, Numans ME, Lau J, de Wit NJ, Hungin AP, Bonis PA. Short-term treatment of gastroesophageal reflux disease. J Gen Intern Med 2003;18:755-63.
80. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997;112:1798-810.
81. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333:1106-10.
82. Galmiche JP, Barthelemy F, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: A double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997;11:765-73.
83. Armstrong D, Barkun AN, Chiba N, et al, and CADET HR Investigators. Initial PPI therapy is most effective in the management of heartburn-dominant uninvestigated dyspepsia (UD) in primary care practice (PCP) - The CADET-HR study. Can J Gastroenterol 2002;16(Suppl A):97A. (Abst)
84. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965-73.
85. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998;10:119-24.
86. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: Efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974-9.
87. Vakil N, Fennerty MB. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther 2003;18:559-68.
88. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther 2001;15:1729-36.
89. Klok RM, Postma MJ, van Hour BA, Brouwers JR. Meta-analysis: Comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther 2003;17:1237-45.
90. Armstrong D, Veldhuyzen van Zanten SJO, Barkun AN, et al, and the CAST Study Investigators. Symptom response at one week to predict outcome at four weeks with esomeprazole (E) in heartburn-dominant uninvestigated dyspepsia (HBDUD) patients: The confirmatory acid suppression (CAST) test. Can J Gastroenterol 2003;17(Suppl A):A85. (Abst)
91. van Bommel MJ, Numans ME, de Wit NJ, Stalman WA. Consultations and referrals for dyspepsia in general practice - a one year database survey. Postgrad Med J 2001;77:514-8.
92. Majumdar SR, Soumerai SB, Francis FA, et al. Chronic acid-related disorders are common and underinvestigated. Am J Gastroenterol 2003;98:2409-14.
93. Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why? Am J Gastroenterol 2003;98:51-8.
94. Hansen JM, Bytzer P, Bondesen S, Schaffalitzky de Muckadell OB. Efficacy and outcome of an open access endoscopy service. Dan Med Bull 1991;38:288-90.
95. Quadri A, Vakil N. Health-related anxiety and the effect of open-access endoscopy in US patients with dyspepsia. Aliment Pharmacol Ther 2003;17:835-40.
96. Fennerty MB. The continuum of GERD complications. Cleve Clin J Med 2003;70(Suppl 5):S33-50.
97. Locke GR III. Natural history of nonerosive reflux disease. Is all gastroesophageal reflux disease the same? What is the evidence? Gastroenterol Clin North Am 2002;31(Suppl 4):S59-66.
98. Talley NJ. Natural history of reflux esophagitis: What is the risk of progression and does it matter clinically? Gastroenterol Hepatol 2002;17:1247-9.
99. Manabe N, Yoshihara M, Sasaki A, Tanaka S, Haruma K, Chayama K. Clinical characteristics and natural history of patients with low-grade reflux esophagitis. J Gastroenterol Hepatol 2002;17:949-54.
100. Klinkenberg-Knol EC, Festen HP, Meuwissen SG. Pharmacological management of gastro-oesophageal reflux disease. Drugs 1995;49:695-710.
101. Dent J, Talley NJ. Overview: Initial and long-term management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003;17(Suppl 1):53-7.
102. Maton PN. Profile and assessment of GERD pharmacotherapy. Cleve Clin J Med 2003;70(Suppl 5):S51-70.
103. Tutuian R, Castell DO. Management of gastroesophageal reflux disease. Am J Med Sci 2003;326:309-18.
104. Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion 2001;64:205-13.
105. Howden CW. Potent versus mild acid suppression in peptic ulcer disease. Hepatogastroenterology 1992;39(Suppl 1):45-6.
106. Freston JW. Long-term acid control and proton pump inhibitors: Interactions and safety issues in perspective. Am J Gastroenterol 1997;92(Suppl 4):51S-7S.
107. Howden CW, Henning JM, Huang B, Lukasik N, Freston JW. Management of heartburn in a large, randomized, community-based study: Comparison of four therapeutic strategies. Am J Gastroenterol 2001;96:1704-10. (Erratum in 2001;96:2809).
108. Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001;121:1095-100.
109. Bardhan KD, Muller-Lissner S, Bigard MA, et al. Symptomatic gastro-oesophageal reflux disease: Double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. BMJ 1999;318:502-7.
110. Quartero AO, Numans ME, Post MW, de Melker RA, de Wit NJ. One-year prognosis of primary care dyspepsia: Predictive value of symptom pattern, Helicobacter pylori and GP management. Eur J Gastroenterol Hepatol 2002;14:55-60.
111. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999;13:907-14.
112. Talley NJ, Venables TL, Green JR, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: A placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002;14:857-63.
113. Wahlqvist P, Junghard O, Higgins A, Green J. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: Comparison of on-demand esomeprazole with conventional omeprazole strategies. Pharmacoeconomics 2002;20:267-77.
114. Bytzer P. On-demand therapy for gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2001;13(Suppl 1):S19-22.
115. Porro GB, Pace F. Rationale and efficacy of medical therapy for gastrooesophageal reflux disease. J Intern Med 1993;234:387-96.
116. 2-receptor antagonists or proton pump inhibitors for GERD patients. Aliment Pharmacol Ther 2005 (In press)
117. Spechler SJ. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Study Group. N Engl J Med 1992;326:786-92.
118. Campos GM, Peters JH, DeMeester TR, et al. Multivariate analysis of factors predicting outcomes after laparoscopic Nissen fundoplication. J Gastrointest Surg 1999;3:292-300.
119. McMahon RL, Mercer CD. National trends in gastroesophageal reflux surgery. Can J Surg 2000;43:48-52.
120. Nilsson G, Larsson S, Johnsson F. Randomized clinical trial of laparoscopic versus open fundoplication: Evaluation of psychological well-being and changes in everyday life from a patient perspective. Scand J Gastroenterol 2002;37:385-91.
121. Chrysos E, Tsiaoussis J, Athanasakis E, Zoras O, Vassilakis JS, Xynos E. Laparoscopic vs open approach for Nissen fundoplication. A comparative study. Surg Endosc 2002;16:1679-84.
122. Wenner J, Nilsson G, Oberg S, Melin T, Larsson S, Johnsson F. Short-term outcome after laparoscopic and open 360 degrees fundoplication. A prospective randomized trial. Surg Endosc 2001;15:1124-8.
123. Luostarinen M, Virtanen J, Koskinen M, Matikainen M, Isolauri J. Dysphagia and oesophageal clearance after laparoscopic versus open Nissen fundoplication. A randomized, prospective trial. Scand J Gastroenterol 2001;36:565-71.
124. Nilsson G, Larsson S, Johnsson F. Randomized clinical trial of laparoscopic versus open fundoplication: Blind evaluation of recovery and discharge period. Br J Surg 2000;87:873-8.
125. Bais JE, Bartelsman JF, Bonjer HJ, et al. Laparoscopic or conventional Nissen fundoplication for gastro-oesophageal reflux disease: Randomised clinical trial. The Netherlands Antireflux Surgery Study Group. Lancet 2000;355:170-4.
126. Heikkinen TJ, Haukipuro K, Bringman S, Ramel S, Sorasto A, Hulkko A. Comparison of laparoscopic and open Nissen fundoplication 2 years after operation. A prospective randomized trial. Surg Endosc 2000;14:1019-23.
127. Lundell L, Miettinen P, Myrvold HE, et al. Continued (5-year) follow-up of a randomized clinical study comparing antireflux surgery and omeprazole in gas gastroesophageal reflux disease. J Am Coll Surg 2001;192:172-81.
128. Triadafilopoulos G, DiBaise JK, Nostrant TT, et al. The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the US open label trial. Gastrointest Endosc 2002;55:149-56.
129. Johnson DA, Ganz R, Aisenberg J, et al. Endoscopic implantation of enteryx for treatment of GERD: 12-month results of a prospective, multicenter trial. Am J Gastroenterol 2003;98:1921-30.
130. Fennerty MB. Endoscopic suturing for treatment of GERD. Gastrointest Endosc 2003;57:390-5.
131. Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: Systematic review. BMJ 2003;326:737.
132. Sharma P, Vakil N. Review article: Helicobacter pylori and reflux disease. Aliment Pharmacol Ther 2003;17:297-305.
133. Vigneri S, Termini R, Savarino V, Pace F. Review article: Is Helicobacter pylori status relevant in the management of GORD? Aliment Pharmacol Ther 2000;14(Suppl 3):31-42.
134. Malfertheiner P, Gerards C. Helicobacter pylori infection and gastro-oesophageal reflux disease: Coincidence or association? Baillieres Best Pract Res Clin Gastroenterol 2000;14:731-41.
135. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442-7.
136. Morini S, Zullo A, Hassan C, Lorenzetti R, Stella F, Martini MT. Gastric cardia inflammation: Role of Helicobacter pylori infection and symptoms of gastroesophageal reflux disease. Am J Gastroenterol 2001;96:2337-40.
137. Schwizer W, Thumshim M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: A randomized controlled trial. Lancet 2001;357:1738-42.
138. Verma S, Giaffer MH. Helicobacter pylori eradication ameliorates symptoms and improves quality of life in patients on long-term acid suppression. A large prospective study in primary care. Dig Dis Sci 2002;47:1567-74.
139. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001; 121:1120-6.
140. Cremonini F, Di Caro S, Delgado-Aros S, et al. Meta-analysis: The relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003;18:279-89.
141. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018-22.
142. Yamada T, Miwa H, Fujino T, Hirai S, Yokoyama T, Sato N. Improvement of gastric atrophy after Helicobacter pylori eradication therapy. J Clin Gastroenterol 2003;36:405-10.
143. Ohkusa T, Fujiki K, Takashimizu I, et al. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med 2001;134:380-6.
144. Satoh K. Does eradication of Helicobacter pylori reverse atrophic gastritis or intestinal metaplasia? Data from Japan. Gastroenterol Clin North Am 2000;29:829-35.
145. Ohkuma K, Okada M, Murayama H, et al. Association of Helicobacter pylori infection with atrophic gastritis and intestinal metaplasia. J Gastroenterol Hepatol 2000;15:1105-12.
146. Kim N, Lim SH, Lee KH, Choi SE. Long-term effect of Helicobacter pylori eradication on gastric metaplasia in patients with duodenal ulcer. J Clin Gastroenterol 1998;27:246-52.
147. DeLuca VA Jr, West AB, Haque S, et al. Long-term symptom patterns, endoscopic findings, and gastric histology in Helicobacter pylori-infected and -uninfected patients. J Clin Gastroenterol 1998;26:106-12.
148. Zhou L, Sung JJ, Lin S, et al. A five-year follow-up study on the pathological changes of gastric mucosa after H pylori eradication. Chin Med J (Engl) 2003;116:11-4.
149. Satoh K, Kimura K, Takimoto T, Kihira K. A follow-up study of atrophic gastritis and intestinal metaplasia after eradication of Helicobacter pylori. Helicobacter 1998;3:236-40.
150. Moayyedi P, Feltbower R, Brown J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: A randomised controlled trial. Leeds HELP Study Group. Lancet 2000;355:1665-9.
151. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2001;(1):CD002096. (Update in: Cochrane Database Syst Rev 2003;(1):CD002096).
152. Wildner-Christensen M, Moller Hansen J, Schaffalitzky De Muckadell OB. Rates of dyspepsia one year after Helicobacter pylori screening and eradication in a Danish population. Gastroenterology 2003;125:372-9.
153. Manes G, Menchise A, de Nucci C, Balzano A. Empirical prescribing for dyspepsia: Randomised controlled trial of test and treat versus omeprazole treatment. BMJ 2003;326:1118.
154. Graham DY. Can therapy even be denied for Helicobacter pylori infection? Gastroenterology 1997;113(Suppl 6):S113-7.
155. Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995;9(Suppl 2):59-69.
156. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spenard J. Bismuth,based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: A prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003;98:562-7.
157. Bardhan K, Bayerdorffer E, Veldhuyzen Van Zanten SJ, et al. The HOMER Study: The effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection. Helicobacter 2000;5:196-201.
158. Veldhuyzen van Zanten S, Hunt RH, Cockeram A, et al. Adding once-daily omeprazole 20 mg to metronidazole/amoxicillin treatment for Helicobacter pylori gastritis: A randomized, double-blind trial showing the importance of metronidazole resistance. Am J Gastroenterol 1998;93:5-10.
159. Best LM, Haldane DJM, Veldhuyzen van Zanten SJO. Susceptibility of Canadian Strains of Helicobacter pylori to metronidazole and clarithromycin using four assay methods. Can J Gastroenterol 1998;12(Suppl A):106A(S92).
160. Fallone CA. Epidemiology of the antibiotic resistance of Helicobacter pylori in Canada. Can J Gastroenterol 2000;14:879-82.
161. Gisbert JP, Gonzalez L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: A meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000;14:1319-28.
162. Laheij RJF, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection - a meta-analysis. Aliment Pharmacol Ther 1999;13:857-64.
163. Fischbach LA, Goodman KJ, Feldman M, Aragaki C. Sources of variation of Helicobacter pylori treatment success in adults worldwide: A meta-analysis. Int J Epidemiol 2002;31:128-39.
164. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology 2002; 123:1763-9.
165. Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: Comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;18:647-54.
166. Hunt R, Thomson AB. Canadian Helicobacter pylori consensus conference. Canadian Association of Gastroenterology. Can J Gastroenterol 1998;12:31-41.
167. 2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;17:1229-36.
168. Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002;16:1047-57.
169. Graham DY, Opekun AR, Hammoud F, et al. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol 2003;98:1005-9.
170. Chiba N, Veldhuyzen Van Zanten SJ. 13C-Urea breath tests are the noninvasive method of choice for Helicobacter pylori detection. Can J Gastroenterol 1999;13:681-3.
171. Malfertheiner P, Megraud F, O'Morain C, et al; European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
172. Mirshahi F, Fowler G, Patel A, Shaw G. Omeprazole may exert both a bacteriostatic and a bacteriocidal effect on the growth of Helicobacter pylori (NCTC 11637) in vitro by inhibiting bacterial urease activity. J Clin Pathol 1998;51:220-4.
173. Nakao M, Malfertheiner F. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter 1998; 3:21-7.
174. Savarino V, Bisso G, Pivari M, et al. Effect of omeprazole and ranitidine on the accuracy of 13C-urea breath test (UBT). Gut 1998;43:A51 (Abst)
175. Savarino V, Vigneri S, Celle G. The 13C urea breath test in the diagnosis of Helicobacter pylori infection. Gut 1999;45(Suppl 1):I18-22.
176. Dulbecco P, Gambaro C, Bilardi C, et al. Impact of long-term ranitidine and pantoprazole on accuracy of [13C] urea breath test. Dig Dis Sci 2003;48:315-21.
177. Chey WD, Spybrook M, Carpenter S, et al. Prolonged effect of omeprazole on the 14C-urea breath test. Am J Gastroenterol 1996;91:89-92.
178. Katelaris PH, Connor SJ, Seow F, et al. The effect of short-term omeprazole use on the accuracy of 13C-urea breath test in Helicobacter pylori infected patients. Gut 1998;43(Suppl 2):A53. (Abst)
179. Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB. Effect of proton-pump inhibitor therapy on diagnostic testing of Helicobacter pylori. Ann Intern Med 1998;129:547-50.
180. El-Nujumi A, Hilditch TE, Williams C, McColl KE. Current or recent proton pump inhibitor therapy markedly impairs the accuracy of the [14C] urea breath test. Eur J Gastroenterol Hepatol 1998;10:759-64.
181. McColl KE, el-Nujumi A, Murray L, et al. The Helicobacter pylori breath test: A surrogate marker for peptic ulcer disease in dyspeptic patients. Out 1997;40:302-6.
182. Chey WD, Woods M, Scheiman JM, Nostrant TT, DelValle J. Lansoprazole and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism. Am J Gastroenterol 1997;92:446-50.
183. Cutler AF, Elnaggar M, Brooks E, O'Mara K. Effect of standard and high dose ranitidine on [13C] urea breath test results. Am J Gastroenterol 1998;93:1297-9.
184. Savarino V, Tracci D, Dulbecco P, et al. Negative effect of ranitidine on the results of urea breath test for the diagnosis of Helicobacter pylori. Am J Gastroenterol 2001;96:348-52.
185. Soo S, Moayyedi P, Decks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2000;(2):CD001960. (Update in: Cochrane Database Syst Rev 2003;(1):CD001960).
186. Bolling-Sternevald E, Lauritsen K, Aalykke C, et al. Effect of profound acid suppression in functional dyspepsia: A double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 2002;37:1395-402.
187. Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: Double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998;12:1055-65.
188. Veldhuyzen van Zanten S, Chiba N, Armstrong D, et al, and CADET-HN Investigators. A double-blind randomised controlled trial comparing omeprazole (Ome), ranitidine (Ran), cisapride (Cis) and placebo (Pla) in 512 Helicobacter pylori (Hp) negative primary care patients with uninvestigated dyspepsia (UD) - The CADET-HN Study. Can J Gastroenterol 2002;16(Suppl A):5A. (Abst)
189. Delaney BC, Innes MA, Deeks J, et al. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2001;(3):CD001961. (Update in: Cochrane Database Syst Rev 2003;(2):CD001961).
190. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2003;(1):CD001960. (Updated in: Database Syst Rev 2003;(2):CD001961).
191. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: A meta-analysis. Am J Gastroenterol 2001;96:689-96.
192. Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: Better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000;14:1267-72.
193. Katz PO, Hatlebakk JG, Castell DO. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther 2000;14:709-14.
194. Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998;12:1235-40.
195. Chiverton SG, Howden CW, Burget DW, Hunt RH. Omeprazole (20 mg) daily given in the morning or evening: A comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration. Aliment Pharmacol Ther 1992;6:103-11.
196. Tougas G, Chen Y, Hwang P, Liu MM, Eggleston A. Prevalence and impact of upper gastrointestinal symptoms in the Canadian population: Findings from the DIGEST study. Domestic/International Gastroenterology Surveillance Study. Am J Gastroenterol 1999;94:2845-54.
197. Maton PN, Burton ME. Antacids revisited. A review of their clinical pharmacology and recommended therapeutic use. Drugs 1999;57:855-70.
198. Mullane J, Fung K, Starkey P, et al. A comparison of the effect of a single dose of either calcium carbonate (1 g) or famotidine (10 mg) on intragastric pH in normal healthy subjects. Gastroenterology 1997;112:A246. (Abst)
199. Collings KL, Rodriguez-Stanley S, Proskin HM, Robinson M, Miner PB Jr. Clinical effectiveness of a new antacid chewing gum on heartburn and oesophageal pH control. Aliment Pharmacol Ther 2002;16:2029-35.
200. Robinson M, Rodriguez-Stanley S, Miner PB, McGuire AJ, Fung K, Ciociola AA. Effects of antacid formulation on postprandial oesophageal acidity in patients with a history of episodic heartburn. Aliment Pharmacol Ther 2002;16:435-43.
201. Reilly TG, Mann SG, Panos MZ, Walt RP. Low-dose famotidine and cimetidine in single post-prandial doses: A placebo controlled comparative study of overnight pH. Gut 1995;37:325-8.
202. Hamilton MI, Sercombe J, Pounder RE. Decrease of intragastric acidity in healthy subjects dosed with ranitidine 75 mg, cimetidine 200 mg, or placebo. Dig Dis Sci 2002;47:54-7.
203. Sihvo S, Hemminki E. Self-medication of dyspepsia: How appropriate is it? Scand J Gastroenterol 1997;32:855-61.
204. Mandel KG, Daggy BP, Brodie DA, Jacoby HI. Review article: Alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther 2000;14:669-90.
205. Mann SG, Murakami A, McCarroll K, et al. Low dose famotidine in the prevention of sleep disturbance caused by heartburn after an evening meal. Aliment Pharmacol Ther 1995;9:395-401.
206. Paul K, Redman CM, Chen M. Effectiveness and safety of nizatidine, 75 mg, for the relief of episodic heartburn. Aliment Pharmacol Ther 2001;15:1571-7.
207. Feldman M. Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. A randomized controlled trial. JAMA 1996;275:1428-31.
208. Thompson Coon J, Ernst E. Systematic review: Herbal medicinal products for non-ulcer dyspepsia. Aliment Pharmacol Ther 2002;16:1689-99.
209. Broussard CN, Richter JE. Treating gastro-oesophageal reflux disease during pregnancy and lactation: What are the safest therapy options? Drug Saf 1998;19:325-37.
210. Winbery SL, Blaho KE. Dyspepsia in pregnancy. Obstet Gynecol Clin North Am 2001;28:333-50.
211. Adams S. Understanding indigestion and GORD. Prof Care Mother Child 1999;9:143-6.
212. Alvarez-Sanchez A, Rey E, Achem SR, Diaz-Rubio M. Does progesterone fluctuation across the menstrual cycle predispose to gastroesophageal reflux? Am J Gastroenterol 1999;94:1468-71.
213. Dajani EZ. Gastroesophageal reflux disease: Pathophysiology and pharmacology overview. J Assoc Acad Minor Phys 2000;11:7-11.
214. Nikfar S, Abdollahi M, Moretti ME, Magee LA, Koren G. Use of proton pump inhibitors during pregnancy and rates of major malformations: A meta-analysis. Dig Dis Sci 2002;47:1526-9.
215. Larson JD, Patatanian E, Miner PB Jr, Rayburn WF, Robinson MG. Double-blind, placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy. Obstet Gynecol 1997;90:83-7.
216. Williamson C. Drugs in pregnancy. Gastrointestinal disease. Best Pract Res Clin Obstet Gynaecol 2001;15:937-52.
217. Atallah AN, Hofmeyr GJ, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 2000;1:CD001059.
218. Candelli M, Carloni E, Armuzzi A, et al. Role of sucralfate in gastrointestinal diseases. Panminerva Med 2000;42:55-9.
219. Henry A, Crowther C. Patterns of medication use during and prior to pregnancy: The MAP study. Aust N Z J Obstet Gynaecol 2000;40:165-72.
220. Kennie N, Por CP, Evans MF. Does ranitidine work for gastroesophageal symptoms during pregnancy? Can Fam Physician 1998;44:761-2.
221. Rayburn W, Liles E, Christensen H, Robinson M. Antacids vs antacids plus non-prescription ranitidine for heartburn during pregnancy. Int J Gynaecol Obstet 1999;66:35-7.
222. Ruigomez A, Garcia Rodriguez LA, Cattaruzzi C, et al. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol 1999;150:476-81.
223. Lalkin A, Loebstein R, Addis A, et al. The safety of omeprazole during pregnancy: A multicenter prospective controlled study. Am J Obstet Gynecol 1998;179:727-30.
224. Gastro-oesophageal reflux during pregnancy: Treat with care. Drug Ther Perspect 1999;13:7-11.
225. Marshall JK, Thompson AB, Armstrong D. Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation. Can J Gastroenterol 1998;12:225-7.
226. Soo S, Moayyedi P, Deeks J, Delaney B, Lewis M, Forman D. Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2001;(4):CD002301.
227. Lee S, Park M, Choi S, Nah Y, Abbey SE, Rodin G. Stress, coping, and depression in non-ulcer dyspepsia patients. J Psychosom Res 2000;49:93-9.
228. Drossman DA. Importance of the psyche in heartburn and dyspepsia. Aliment Pharmacol Ther 1997;11(Suppl 2):57-67.
229. Wiklund I, Butler-Wheelhouse P. Psychosocial factors and their role in symptomatic gastroesophageal reflux disease and functional dyspepsia. Scand J Gastroenterol Suppl 1996;220:94-100.
230. O'Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999;48:980-90.
231. de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: Population based case-control study. BMJ 1999;319:1106-9.
232. van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: Retrospective cohort study. BMJ 2001;323:655-8.
233. Hamilton J, Guthrie E, Creed F, et al. A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 2000;119:661-9.